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Release of C-Reactive Protein in Response to Inflammatory Cytokines by Human Adipocytes:
Linking Obesity to Vascular Inflammation
To the Editor: Obesity, the most common nutritional disorder in
industrialized countries, is associated with increased cardiovascular
mortality and morbidity (1). C-reactive protein (CRP), an acute-
phase protein and an important predictor of future cardiovascular
events in apparently healthy men and women (2), has been thought
to be synthesized in the liver following stimulation by cytokines,
such as interleukin (IL)-1-beta, IL-6, and tumor necrosis factor
(TNF)-alpha (3). Recently, however, the extrahepatic synthesis of
CRP was found to occur under similar proinflammatory conditions
(4). There is also some evidence for the presence of the CRP
message in human adipose tissue (5). In the present study, we
investigated whether CRP is produced by cells in adipose tissue in
response to inflammatory stimuli using an in vitro model and
whether this phenomenon might be modulated using anti-
inflammatory drugs.
Primary cultures of human adipocytes from adipose tissue were
performed as previously described (6), and the isolated adipocytes
were incubated under the conditions required for each particular
experiment. C-reactive protein levels in the cell supernatants were
measured using an enzyme-linked immunoadsorbent assay specific
for human CRP. The minimum concentration detected by the
assay was 1.6 ng/ml. All experiments were performed in duplicate.
Adipocytes were cultured in tubes, and cells from different donors
were used for each experiment. The cells were incubated with
recombinant human IL-1-beta (25 ng/ml), IL-6 (10 ng/ml),
resistin (100 ng/ml), adiponectin (1 g/ml), or leptin (40 ng/ml).
For the modulation experiments, at the same time of stimulation,
cells were incubated with vehicle (dimethylsulfoxide), aspirin (5
mol/l), troglitazone (10 mol/l), or fluvastatin (5 mol/l). Doses
and timing were chosen on the basis of findings from previous
experiments. After 48 h, the culture supernatants were concen-
trated and assayed for CRP levels. Data are presented as the mean
value  SD and were analyzed using one-way analysis of variance
followed by the Scheffe test for multiple comparisons. Statistical
significance was indicated at the level p  0.05.
Figure 1A shows a representative experiment (n  4) of CRP
production by adipocytes following treatment with inflammatory
cytokines. The incubation of adipocytes with IL-1-beta or IL-6
resulted in more than doubling of CRP production compared with
the production in unstimulated cells (p  0.05). Adipocytes
treated with either adiponectin and leptin did not produce CRP
compared with unstimulated cells. Finally, resistin induced an
almost three-fold increase in CRP production (p 0.01). In order
to mimic more pathophysiological conditions, we used combina-
tions of the active stimuli together (n  3), and the results are
shown in Figure 1B. Combination of IL-1-beta and IL-6 induced
an almost three-fold increase in CRP production (p  0.01). The
addition of resistin led to an even larger increase in CRP
production (p  0.01). Figure 2 shows the effect of fluvastatin,
troglitazone, and aspirin on the production of CRP. Treatment
with fluvastatin or troglitazone led to a significant, but not
complete, inhibition of CRP release from adipocytes (p  0.05).
Finally, a larger, but still not complete, modulation of CRP release
from adipocytes was observed after treatment with aspirin (p 
0.05).
In the present study, we showed for the first time the production
of a major acute-phase protein, CRP, by adipocytes isolated from
human adipose tissue in response to inflammatory cytokines,
thereby suggesting a new link between obesity and vascular
inflammation.
Adipose tissue secretes various bioactive substances, generally
referred to as adipocytokines, including IL-6, TNF-alpha, leptin,
adiponectin, and resistin, that may contribute to obesity-linked
metabolic and vascular diseases (7). In addition, obese individuals
have high circulating levels of a range of inflammatory markers
produced by adipose tissue, including IL-1-beta and IL-6 (8),
cytokines responsible for both hepatic and extrahepatic production
of CRP (4). In several studies, high plasma levels of this acute-
phase protein were strongly associated with obesity and obesity-
related diseases (9). There is recent evidence of CRP expression in
human adipose tissue as well. Ouchi et al. (5) showed CRP mRNA
expression in human adipose. However, they made no attempt to
investigate the stimuli able to induce CRP. Here, we found that
human adipocytes cultured in vitro produced CRP after exposure
for 48 h to inflammatory cytokines, such as IL-1-beta, IL-6, and
Figure 1. (A) Effect of interleukin (IL)-1-beta (1), IL-6 (6), adiponectin
(A), leptin (L), or resistin (R) on C-reactive protein (CRP) production in
human adipocytes. (B) Effect of combination of stimuli (1  6, 1  6 
R) on CRP production in human adipocytes. Values are expressed as the
“-fold” increase in CRP levels compared with levels in untreated cells, and
each bar represents the mean SD of duplicate determinations. *p 0.05
vs. untreated cells; **p  0.01 vs. untreated cells.
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resistin. Interestingly, treatment of adipocytes with two other adipo-
cytokines, adiponectin and leptin, did not lead to CRP production.
Furthermore, treatment with several anti-inflammatory drugs shown
to be effective in reducing serum CRP levels, such as aspirin,
troglitazone, and fluvastatin (10,11), leads to reduction, but not
complete inhibition, of CRP release from adipocytes. This might
explain in part the beneficial cardiovascular effects of these drugs.
In conclusion, our study demonstrates that human adipocytes
can produce CRP under the stimulation of several proinflamma-
tory cytokines; moreover, CRP production may be modulated by
selected pharmacologic intervention. The mechanism(s) underly-
ing these findings are not fully defined, and further studies are
needed in this area.
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Letters to the Editor
Physiological Mechanisms of
Atrially Induced Heart Rate Turbulence
We read with interest the study by Vikman et al. (1) and are pleased
that this respectable group shares our interest in atrially induced heart
rate turbulence. Although we understand the reasoning behind the
suggestion that “vagal inhibition in response to premature atrial
excitation is absent, or even that transient enhancement of vagal
outflow occurs before atrial fibrillation,” we would like to offer the
investigators an alternative explanation for their findings.
We all would surely agree that less effective ventricular contraction
and compensatory pause after premature beats is responsible for
transient hemodynamic deficit, missed baroreflex afferent input, and
early vagal inhibition. This mechanism is applicable for both ventric-
ular and atrial premature complexes (APCs). Autonomic modulation
of sinus nodal discharge after APCs may explain values of turbulence
onset (TO) 0. When TO 0 is found, the underlying mechanism
has to be different. The mechanism suggested by Vikman et al.,
namely the temporary direct suppression of sinus node automaticity, is
certainly plausible. This phenomenon, which may mask (or over-
whelm) the autonomic component of early acceleration, has been
previously demonstrated (2).
Because of a missing relationship between TO and APC prema-
turity, Vikman et al. rejected the hypothesis that sinus resetting is the
predominant factor influencing the temporal changes of TO. How-
ever, this lack of correlation seems to us compatible rather than
incompatible with sinus nodal resetting. Autonomically mediated TO
should be positively related to the APC coupling interval, whereas TO
mediated by direct suppression of sinus node automaticity should be
negatively related to the APC coupling interval. Thus, coexistence of
both mechanisms may effectively offset the relationship between TO
and APC prematurity.
Although TO and turbulence slope after ventricular premature
complexes and turbulence slope after APCs reflect heart rate vagal
modulation, this is not the case for TO after APCs (3). We have not
found any significant relationship between atrial TO and other
previously established surrogates of heart rate vagal modulation in
large Holter databases (Wichterle et al., unpublished data, 2005).
We thus wonder whether Vikman et al. (1) would agree that their
finding might be interpreted as either 1) temporal decrease of vagal
modulation, or 2) temporal change of APC prematurity (which
cannot be exactly assessed fromHolter recording) and/or site of origin
of APCs—all factors potentially facilitating sinus node resetting. We
believe that the latter possibility might be more probable because none
of the other investigated indices of autonomic modulation (including
Figure 2. Modulation of C-reactive protein (CRP) synthesis in human
adipocytes treated with dimethylsulfoxide (DMSO) (control), fluvastatin
(FLUVA), troglitazone (TROG), or aspirin (ASA). Values are expressed
as the “-fold” increase in the level compared with the level in untreated
cells, and each bar represents the mean  SD of duplicate determinations.
*p  0.05 vs. combination of cytokines. 1  6  R  interleukin-1 
interleukin-6  resistin.
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